Kangyuan Huawei Pharmaceutical

Kangyuan Huawei Pharmaceutical is a key subsidiary of Jiangsu Kangyuan Pharmaceutical (Kanion), a leading Chinese pharmaceutical group specializing in the modernization of Traditional Chinese Medicine (TCM) and the development of innovative chemical drugs. The company focuses on the research, development, and large-scale manufacturing of therapeutic products for gynecology, orthopedics, cardiovascular diseases, and anti-infectives. Operating from state-of-the-art GMP-certified facilities, Kangyuan Huawei integrates traditional medical knowledge with modern pharmacological standards to produce evidence-based treatments. The firm is integral to the parent company's R&D strategy, supporting a diverse portfolio that includes proprietary Chinese medicines, chemical generics, and emerging biologics. Its products are widely utilized in the Chinese domestic market, with an increasing focus on meeting international clinical quality standards.